WebSify
Follow us on
Mail
Print

Pfizer to pay $55 million in drug misbranding case

Source : AP
Last Updated: Wed, Dec 12, 2012 19:15 hrs

The Justice Department says Pfizer Inc. will pay $55 million to resolve allegations that its subsidiary Wyeth LLC promoted the drug Protonix for uses that were not approved by the Food and Drug Administration.

In a written statement from its New York office, Pfizer, which acquired Wyeth in October 2009 years after the alleged misconduct, said that Pfizer was not a target or a subject of the case.

Wyeth obtained FDA approval to promote Protonix only for short-term treatment of erosive esophagitis. The condition is associated with gastro-esophageal reflux disease. Wyeth allegedly promoted Protonix for all forms of GERD from February 2000 to June 2001.

GERD is a condition in which food or liquid leak backwards from the stomach into the esophagus.

Pfizer's statement specifically denied allegations of wrongdoing.



blog comments powered by Disqus
most popular on facebook
talking point on sify finance